Lipocalin 2 is essential for chronic kidney disease progression in mice and humans

Journal of Clinical Investigation

Volumn 120, Issue 11, 2010, Pages 4065-4076

  Viau, Amandine ^a   El Karoui, Khalil ^a   Laouari, Denise ^a   Burtin, Martine ^a   Nguyen, Clément ^a   Mori, Kiyoshi ^b   Pillebout, Evangéline ^a   Berger, Thorsten ^c   Mak, Tak Wah ^c   Knebelmann, Bertrand ^a   Friedlander, Gérard ^a   Barasch, Jonathan ^b   Terzi, Fabiola ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; KIDNEY POLYCYSTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANIMALS; CELL LINE; DISEASE PROGRESSION; EPIDERMAL GROWTH FACTOR; FEMALE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIPOCALINS; MALE; MICE; MICE, INBRED STRAINS; MICE, KNOCKOUT; MIDDLE AGED; ONCOGENE PROTEINS; POLYCYSTIC KIDNEY DISEASES; PROTO-ONCOGENE PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RENAL INSUFFICIENCY, CHRONIC; YOUNG ADULT;

EID: 78049434336     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI42004     Document Type: Article

References (54)

1. Collins AJ, et al. US Renal Data System: excerpts from the USRDS 2005 Annual Data Report. Am J Kidney Dis. 2006;47(suppl 1):S1-S286.
2. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365(9456):331-340. (Pubitemid 40139112)
3. Kidney and Urologic Diseases Statistics for the United States. National Kidney and Urologic Diseases Information Clearinghouse (NKUDIC) Web Site. http://kidney.niddk.nih.gov/kudiseases/pubs/kustats/index.htm. Accessed August 10, 2010.
4. Hostetter TH. Progression of renal disease and renal hypertrophy. Annu Rev Physiol. 1995;57:263-278.
5. Terzi F, et al. Subtotal but not unilateral nephrectomy induces hyperplasia and protooncogene expression. Am J Physiol. 1995;268(5 pt 2):F793-F801.
6. Kliem V, et al. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int. 1996;49(3):666-678.
7. Pillebout E, et al. JunD protects against chronic kidney disease by regulating paracrine mitogens. J Clin Invest. 2003;112(6):843-852. (Pubitemid 38063742)
8. Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest. 2006;116(2):288-296. (Pubitemid 43228342)
9. Esposito C, He CJ, Striker GE, Zalups RK, Striker LJ. Nature and severity of the glomerular response to nephron reduction is strain-dependent in mice. Am J Pathol. 1999;154(3):891-897. (Pubitemid 29122608)
10. Kren S, Hostetter TH. The course of the remnant kidney model in mice. Kidney Int. 1999;56(1):333-337. (Pubitemid 29300552)
11. Ma LJ, Fogo AB. Model of robust induction of glomerulosclerosis in mice: importance of genetic background. Kidney Int. 2003;64(1):350-355.
12. Pillebout E, et al. Proliferation and remodeling of the peritubular microcirculation after nephron reduction: association with the progression of renal lesions. Am J Pathol. 2001;159(2):547-560. (Pubitemid 32751085)
13. Flower DR, North AC, Attwood TK. Mouse oncogene protein 24p3 is a member of the lipocalin protein family. Biochem Biophys Res Commun. 1991;180(1):69-74.
14. Schlehuber S, Skerra A. Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". Drug Discov Today. 2005;10(1):23-33.
15. Smith LA, et al. Development of polycystic kidney disease in juvenile cystic kidney mice: insights into pathogenesis, ciliary abnormalities, and common features with human disease. J Am Soc Nephrol. 2006;17(10):2821-2831.
16. Kuwabara T, et al. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kidney Int. 2009;75(3):285-294.
17. Ding H, et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) is an early biomarker for renal tubulointerstitial injury in IgA nephropathy. Clin Immunol. 2007;123(2):227-234.
18. Paragas N, et al. Urinary NGAL marks cystic disease in HIV-associated nephropathy. J Am Soc Nephrol. 2009;20(8):1687-1692.
19. Berger T, et al. Lipocalin 2-deficient mice exhibit increased sensitivity to Escherichia coli infection but not to ischemia-reperfusion injury. Proc Natl Acad Sci U S A. 2006;103(6):1834-1839.
20. Goetz DH, Holmes MA, Borregaard N, Bluhm ME, Raymond KN, Strong RK. The neutrophil lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol Cell. 2002;10(5):1033-1043. (Pubitemid 36001971)
21. Nankivell BJ, Boadle RA, Harris DC. Iron accumulation in human chronic renal disease. Am J Kidney Dis. 1992;20(6):580-584. (Pubitemid 23031708)
22. Harris DC, Tay YC, Chen J, Chen L, Nankivell BJ. Mechanisms of iron-induced proximal tubule injury in rat remnant kidney. Am J Physiol. 1995;269(2 pt 2):F218-F224.
23. Igarashi P, Somlo S. Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol. 2002;13(9):2384-2398. (Pubitemid 34925250)
24. Schmidt-Ott KM, et al. Dual action of neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol. 2007;18(2):407-413.
25. Zeng F, Singh AB, Harris RC. The role of the EGF family of ligands and receptors in renal development, physiology and pathophysiology. Exp Cell Res. 2009;315(4):602-610.
26. Terzi F, et al. Targeted expression of a dominant-negative EGF-R in the kidney reduces tubulointerstitial lesions after renal injury. J Clin Invest. 2000;106(2):225-234.
27. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721-732.
28. Gunaratnam L, Bonventre JV. HIF in kidney disease and development. J Am Soc Nephrol. 2009;20(9):1877-1887.
29. Devireddy LR, Gazin C, Zhu X, Green MR. A cell-surface receptor for lipocalin 24p3 selectively mediates apoptosis and iron uptake. Cell. 2005;123(7):1293-1305. (Pubitemid 41821786)
30. Holmes MA, Paulsene W, Jide X, Ratledge C, Strong RK. Siderocalin (Lcn 2) also binds carboxymycobactins, potentially defending against mycobacterial infections through iron sequestration. Structure. 2005;13(1):29-41. (Pubitemid 40092472)
31. Flo TH, et al. Lipocalin 2 mediates an innate immune response to bacterial infection by sequestrating iron. Nature. 2004;432(7019):917-921.
32. Saiga H, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol. 2008;181(12):8521-8527.
33. Yang J, Moses MA. Lipocalin 2: a multifaceted modulator of human cancer. Cell Cycle. 2009;8(15):2347-2352.
34. Borregaard N, Cowland JB. Neutrophil gelatinase-associated lipocalin, a siderophore-binding eukaryotic protein. Biometals. 2006;19(2):211-215. (Pubitemid 43794830)
35. Yang J, et al. An iron delivery pathway mediated by a lipocalin. Mol Cell. 2002;10(5):1045-1056.
36. Mori K, et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest. 2005;115(3):610-621.
37. Bolignano D, et al. Neutrophil gelatinase-associated lipocalin in patients with autosomal-dominant polycystic kidney disease. Am J Nephrol. 2007;27(4):373-378. (Pubitemid 47077201)
38. Stone CE, Hall DH, Sundaram MV. Lipocalin signaling controls unicellular tube development in the Caenorhabditis elegans excretory system. Dev Biol. 2009;329(2):201-211.
39. Wei F, et al. Neutrophil gelatinase-associated lipocalin suppresses cyst growth by Pkd1 null cells in vitro and in vivo. Kidney Int. 2008;74(10):1310- 1318.
40. Tang S, Leung JC, Tsang AW, Lan HY, Chan TM, Lai KN. Transferrin up-regulates chemokine synthesis by human proximal tubular epithelial cells: implication on mechanism of tubuloglomerular communication in glomerulopathic proteinuria. Kidney Int. 2002;61(5):1655-1665. (Pubitemid 34437919)
41. Hakroush S, et al. Effects of increased renal tubular vascular endothelial growth factor (VEGF) on fibrosis, cyst formation, and glomerular disease. Am J Pathol. 2009;175(5):1883-1895.
42. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int. 2008;74(7):867-872.
43. Strutz F, et al. Basic fibroblast growth factor expression is increased in human renal fibrogenesis and may mediate autocrine fibroblast proliferation. Kidney Int. 2000;57(4):1521-1538. (Pubitemid 30207911)
44. Stocklin E, Botteri F, Groner B. An activated allele of the c-erbB-2 oncogene impairs kidney and lung function and causes early death of transgenic mice. J Cell Biol. 1993;122(1):199-208.
45. Richards WG, Sweeney WE, Yoder BK, Wilkinson JE, Woychik RP, Avner ED. Epidermal growth factor receptor activity mediates renal cyst formation in polycystic kidney disease. J Clin Invest. 1998;101(5):935-939.
46. Sweeney WE, Chen Y, Nakanishi K, Frost P, Avner ED. Treatment of polycystic kidney disease with a novel tyrosine kinase inhibitor. Kidney Int. 2000;57(1):33-40.
47. Lautrette A, et al. Angiotensin II and EGF receptor cross-talk in chronic kidney diseases: a new therapeutic approach. Nat Med. 2005;11(8):867-874. (Pubitemid 41161119)
48. Leng X, et al. Inhibition of lipocalin 2 impairs breast tumorigenesis and metastasis. Cancer Res. 2009;69(22):8579-8584.
49. Nickolas TL, Barasch J, Devarajan P. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens. 2008;17(2):127-132. (Pubitemid 351253035)
50. Lemley KV. An introduction to biomarkers: applications to chronic kidney disease. Pediatr Nephrol. 2007;22(11):1849-1859.
51. Shepard HM, Brdlik CM, Schreiber H. Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family. J Clin Invest. 2008;118(11):3574-3581.
52. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther. 2007;5(B):463-470.
53. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
54. Diarra-Mehrpour M, et al. Prion protein prevents human breast carcinoma cell line from tumor necrosis factor alpha-induced death. Cancer Res. 2004;64(2):719-727. (Pubitemid 38120915)